<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Other drugs for the management of insomnia in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Other drugs for the management of insomnia in adults</h1>
<div class="graphic"><div class="figure"><div class="ttl">Other drugs for the management of insomnia in adults</div><div class="cntnt"><table cellspacing="0"><colgroup span="6" width="12%"></colgroup><colgroup width="28%"></colgroup> <tbody> <tr> <td class="subtitle1">Other drugs</td> <td class="subtitle1">Mechanism of action</td> <td class="subtitle1">Clinical use*</td> <td class="subtitle1">Adult dose<br/> (usual)</td> <td class="subtitle1">Dose in older adults<br/> (≥65 years)</td> <td class="subtitle1">Half-life<br/> (hours)</td> <td class="subtitle1">Potential for drug interactions<sup>¶</sup></td> </tr> <tr> <td>Doxepin</td> <td>Histamine H1 receptor antagonism<sup>Δ</sup></td> <td>Sleep maintenance insomnia</td> <td>3 to 10 mg<sup>◊</sup></td> <td>3 to 6 mg</td> <td>Long (15 drug; 31 active metabolite)</td> <td> <ul> <li>Moderate</li> <li>Doxepin clearance is largely dependent on CYP2D6</li> <li>Avoid use within two weeks of MAOI administration</li> </ul> </td> </tr> <tr> <td>Ramelteon</td> <td>Melatonin receptor agonist</td> <td>Sleep onset insomnia</td> <td>8 mg</td> <td>8 mg</td> <td>Short (1 to 2.6 drug; 2 to 5 active metabolite)</td> <td> <ul> <li>Moderate</li> <li>Ramelteon clearance is largely dependent on CYP1A2 and CYP2C9</li> </ul> </td> </tr> <tr> <td>Lemborexant</td> <td>Dual orexin receptor antagonist (DORA)</td> <td>Sleep onset or sleep maintenance insomnia</td> <td>5 to 10 mg</td> <td>5 mg</td> <td>Long (17 to 19)</td> <td> <ul> <li>Significant drug interactions</li> <li>Lemborexant clearance is dependent on CYP3A4</li> <li>If used in combination with mild inhibitors of CYP3A4, recommended dose is 5 mg</li> <li>Avoid use of lemborexant with moderate and strong inhibitors and inducers of CYP3A4</li> </ul> </td> </tr> <tr> <td>Suvorexant</td> <td>DORA</td> <td>Sleep onset or sleep maintenance insomnia</td> <td>10 to 20 mg</td> <td>10 to 15 mg</td> <td>Intermediate (12)</td> <td> <ul> <li>Significant drug interactions</li> <li>Suvorexant clearance is largely dependent on CYP3A</li> <li>If used in combination with moderate inhibitors of CYP3A, recommended dose is 5 mg; may increase to 10 mg</li> <li>Avoid use of suvorexant with strong inhibitors or inducers of CYP3A</li> </ul> </td> </tr> <tr> <td>Daridorexant</td> <td>DORA</td> <td>Sleep onset or sleep maintenance insomnia</td> <td>25 to 50 mg</td> <td>25 to 50 mg</td> <td>Intermediate (8)</td> <td> <ul> <li>Significant drug interactions</li> <li>Daridorexant clearance is largely dependent on CYP3A</li> <li>If used in combination with moderate inhibitors of CYP3A, recommended dose is 25 mg</li> <li>Avoid use of daridorexant with strong inhibitors or moderate/strong inducers of CYP3A</li> </ul> </td> </tr> <tr> <td>Trazodone<sup>§</sup></td> <td>Serotonin 5-HT2A, alpha-1 adrenergic, and histamine H1 receptor antagonism<sup>Δ</sup></td> <td>Sleep onset or sleep maintenance insomnia</td> <td>50 to 100 mg</td> <td>25 to 100 mg</td> <td>Intermediate (10 to 12)</td> <td> <ul> <li>Moderate</li> <li>Trazodone is metabolized by CYP3A4 to an active metabolite; use with caution in combination with other serotonergic drugs</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">Dosing in this table is for adult patients with normal organ (eg, kidney, liver) function. For dosage adjustments, refer to Lexicomp drug information included with UpToDate.</div><div class="graphic_footnotes"><p>CYP: cytochrome P450; MAOI: monoamine oxidase inhibitor; FDA: US Food and Drug Administration.</p>
<p>* Appropriate clinical uses may differ from the FDA-approved indication(s) for a given drug.</p>
<p>¶ For specific drug interactions, including management recommendations and combinations that should be avoided, use Lexi-Interact drug interactions program included with UpToDate.</p>
<p>Δ Although classified as antidepressants, these drugs are not therapeutic for treating depression at the doses used for insomnia.</p>
<p>◊ FDA-approved for insomnia at doses of 3 and 6 mg daily using tablet formulation.</p>
§ Not approved by the FDA for insomnia indication.</div><div id="graphicVersion">Graphic 117512 Version 10.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
